Document 6wbNv4rx1noaLbzMJaozkjKzo

I g e m O C 06 .QOb'Uf R E C E IV E D f)PPT C AR#a_. 36-f? May 15, 2006 06HA 17 AH 6- 00 DuPont Haskell Laboratory for Health and Environmental Sciences Elkton Road, P.O. Box 50 Newark, DE 19714-0050 Via Federal Express Document Processing Center (Mail Code 7407M) Room 6428 Attention: 8(e) Coordinator Office of Pollution Prevention and Toxics U.S. Environmental Protection Agency 1201 Constitution Ave., NW Washington, DC 20460 -o oa Dear 8(e) Coordinator: 8EHQ-0381-0394 Perfluorooctanoate (PFOA) This letter is being submitted as a supplement to our PFOA epidemiology submissions we communicated to the Agency on January 10 and August 4, 2005. Enclosed please find the results of a longitudinal study of serum total cholesterol related to serum PFOA measurements in a group of Washington Works employees that participated at least twice in the voluntary biomonitoring program at the plant over the last 25 years. Using a mixed effects statistical model with repeated measures for the 454 employees with at least two measurements of PFOA, the essential results show an increase of total cholesterol with increasing serum PFOA of about 1 mg/dl cholesterol per 1 ppm PFOA. The major limitations of the study were the lack of information regarding the use and/or start and stop dates of lipid-lowering medications, and the necessity of interpolating cholesterol results between dates of PFOA monitoring. The enclosed poster was presented last week at the American College of Occupational and Environmental Medicine (ACOEM) conference. While DuPont does not believe this information is substantial risk information reportable under TSCA 8(e), DuPont is submitting the information to the TSCA 8(e) office in view of the Agency's continued interest m perfluorinated substances. Sincerely, Q, \\/U6Jb&eJL A. Michael Kaplan, Ph.D. Director - Regulatory Affairs and Occupational Health Enclosure: (1) ^ *#' er* AMK/RWR/RCL: clp (302) 366-5260 89060000324 89060000 324 I ci'f s l 7 3